Molecular profiling of single circulating tumor cells from lung cancer patients

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 52, 2016, Pages E8379-E8386

  Park, Seung Min ^a   Wong, Dawson J ^b   Ooi, Chin Chun ^b   Kurtz, David M ^a,b   Vermesh, Ophir ^a   Aalipour, Amin ^a   Suh, Susie ^c   Pian, Kelsey L ^b   Chabon, Jacob J ^a   Lee, Sang Hun ^d   Jamali, Mehran ^a   Say, Carmen ^a   Carter, Justin N ^a   Lee, Luke P ^d   Kuschner, Ware G ^a,e   Schwartz, Erich J ^a   Shrager, Joseph B ^a   Neal, Joel W ^a,f   Wakelee, Heather A ^a,f   Diehn, Maximilian ^a,f   Nair, Viswam S ^a   Wang, Shan X ^a,b   Gambhir, Sanjiv S ^a   more..

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Stanford University   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d University of California   (United States)

^e VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^f STANFORD CANCER INSTITUTE   (United States)

Author keywords

Circulating tumor cells; Microfluidics; Rare cell sorting; Reverse transcription PCR; Single cell analysis

Indexed keywords

ALDEHYDE DEHYDROGENASE; DEOXYRIBONUCLEASE I; GENOMIC DNA; MAGNETIC NANOPARTICLE; SCATTER FACTOR RECEPTOR; TELOMERASE REVERSE TRANSCRIPTASE; VASCULOTROPIN; VIMENTIN; PTPRC PROTEIN, HUMAN; RECEPTOR TYPE TYROSINE PROTEIN PHOSPHATASE C; TUMOR MARKER;

ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER PATIENT; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULAR BIOLOGY; NON SMALL CELL LUNG CANCER; PATIENT MONITORING; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TUMOR INVASION; ADULT; AGED; BLOOD; CELL COUNT; FEMALE; GENE EXPRESSION REGULATION; LUNG TUMOR; MALE; MICROFLUIDICS; MIDDLE AGED; MUTATION; NANOTECHNOLOGY; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE CELL ANALYSIS; TUMOR EMBOLISM;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CELL COUNT; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKOCYTE COMMON ANTIGENS; LUNG NEOPLASMS; MALE; MICROFLUIDICS; MIDDLE AGED; MUTATION; NANOTECHNOLOGY; NEOPLASTIC CELLS, CIRCULATING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SINGLE-CELL ANALYSIS;

EID: 85007494746     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1608461113     Document Type: Article

References (56)

1. Hanash SM, Baik CS, Kallioniemi O (2011) Emerging molecular biomarkers-bloodbased strategies to detect and monitor cancer. Nat Rev Clin Oncol 8(3):142-150.
2. Krebs MG, et al. (2014) Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol 11(3):129-144.
3. Tibbe AG, et al. (1999) Optical tracking and detection of immunomagnetically selected and aligned cells. Nat Biotechnol 17(12):1210-1213.
4. Nagrath S, et al. (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450(7173):1235-1239.
5. Stott SL, et al. (2010) Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci USA 107(43):18392-18397.
6. Castro CM, et al. (2014) Miniaturized nuclear magnetic resonance platform for detection and profiling of circulating tumor cells. Lab Chip 14(1):14-23.
7. Talasaz AH, et al. (2009) Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci USA 106(10):3970-3975.
8. Earhart CM, et al. (2014) Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips. Lab Chip 14(1):78-88.
9. Sarioglu AF, et al. (2015) A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Methods 12(7):685-691.
10. Krebs MG, et al. (2012) Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and-independent approaches. J Thorac Oncol 7(2):306-315.
11. Sollier E, et al. (2014) Size-selective collection of circulating tumor cells using Vortex technology. Lab Chip 14(1):63-77.
12. Ozkumur E, et al. (2013) Inertial focusing for tumor antigen-dependent and-independent sorting of rare circulating tumor cells. Sci Transl Med 5(179):179ra47.
13. Li W, et al. (2015) Biodegradable nano-films for capture and non-invasive release of circulating tumor cells. Biomaterials 65:93-102.
14. Lin M, et al. (2014) Nanostructure embedded microchips for detection, isolation, and characterization of circulating tumor cells. Acc Chem Res 47(10):2941-2950.
15. Yoon HJ, et al. (2013) Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol 8(10):735-741.
16. Marrinucci D, et al. (2012) Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol 9(1):016003.
17. Maheswaran S, et al. (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359(4):366-377.
18. Devriese LA, et al. (2012) Circulating tumor cell detection in advanced non-small cell lung cancer patients by multi-marker QPCR analysis. Lung Cancer 75(2):242-247.
19. Sieuwerts AM, et al. (2009) Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res Treat 118(3):455-468.
20. Haber DA, Velculescu VE (2014) Blood-based analyses of cancer: Circulating tumor cells and circulating tumor DNA. Cancer Discov 4(6):650-661.
21. Powell AA, et al. (2012) Single cell profiling of circulating tumor cells: Transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 7(5):e33788.
22. Chen CL, et al. (2013) Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate 73(8):813-826.
23. Jemal A, et al. (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90.
24. Shepherd FA, et al.; National Cancer Institute of Canada Clinical Trials Group (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123-132.
25. Solomon BJ, et al.; PROFILE 1014 Investigators (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371(23):2167-2177.
26. Dimov IK, et al. (2014) Discriminating cellular heterogeneity using microwell-based RNA cytometry. Nat Commun 5:3451.
27. Park SM, et al. (2016) Dual transcript and protein quantification in a massive single cell array. Lab Chip 16(19):3682-3688.
28. Al-Soud WA, Radström P (2001) Purification and characterization of PCR-inhibitory components in blood cells. J Clin Microbiol 39(2):485-493.
29. Ni X, et al. (2013) Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci USA 110(52):21083-21088.
30. Sozzi G, et al. (2003) Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21(21):3902-3908.
31. Kubo T, et al. (2009) MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer 124(8):1778-1784.
32. Tsao M-S, et al. (1993) Hepatocyte growth factor/scatter factor is an autocrine factor for human normal bronchial epithelial and lung carcinoma cells. Cell Growth Differ 4(7):571-579.
33. Kato Y, et al. (2010) Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: Immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 5(10):1551-1558.
34. Satelli A, et al. (2014) Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res 74(6):1645-1650.
35. Krebs MG, et al. (2011) Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 29(12):1556-1563.
36. Al-Saad S, et al. (2008) The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Br J Cancer 99(9):1476-1483.
37. Jiang F, et al. (2009) Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 7(3):330-338.
38. Park SM, Sabour AF, Son JH, Lee SH, Lee LP (2014) Toward integrated molecular diagnostic system (iMDx): Principles and applications. IEEE Trans Biomed Eng 61(5):1506-1521.
39. Kobayashi S, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8):786-792.
40. Sundaresan TK, et al. (2016) Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clin Cancer Res 22(5):1103-1110.
41. Newman AM, et al. (2014) An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20(5):548-554.
42. Ramsköld D, et al. (2012) Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. Nat Biotechnol 30(8):777-782.
43. Lohr JG, et al. (2014) Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol 32(5):479-484.
44. Miyazu YM, et al. (2005) Telomerase expression in noncancerous bronchial epithelia is a possible marker of early development of lung cancer. Cancer Res 65(21):9623-9627.
45. Lantuejoul S, et al. (2004) Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. Br J Cancer 90(6):1222-1229.
46. Zhu CQ, et al. (2006) Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer. Br J Cancer 94(10):1452-1459.
47. Fujita Y, et al. (2003) The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with nonsmall cell lung carcinoma. Cancer 98(5):1008-1013.
48. Miura N, et al. (2006) Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. Cancer Sci 97(12):1366-1373.
49. Tsao M-S, et al. (1998) Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer 20(1):1-16.
50. Sierra JR, Tsao M-S (2011) c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 3(1, Suppl):S21-S35.
51. Sheu C-C, et al. (2006) Combined detection of CEA, CK-19 and c-met mRNAs in peripheral blood: A highly sensitive panel for potential molecular diagnosis of non-small cell lung cancer. Oncology 70(3):203-211.
52. Cheng T-L, et al. (2005) Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer. Chest 128(3):1453-1460.
53. Henegariu O, Heerema NA, Dlouhy SR, Vance GH, Vogt PH (1997) Multiplex PCR: Critical parameters and step-by-step protocol. Biotechniques 23(3):504-511.
54. Earhart CM, Wilson RJ, White RL, Pourmand N, Wang SX (2009) Microfabricated magnetic sifter for high-throughput and high-gradient magnetic separation. J Magn Magn Mater 321(10):1436-1439.
55. Yu M, et al. (2012) RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 487(7408):510-513.
56. Lustberg M, Jatana KR, Zborowski M, Chalmers JJ (2012) Emerging technologies for CTC detection based on depletion of normal cells. Recent Results Cancer Res 195: 97-110.